POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FL OR DLBCL: UPDATED RESULTS OF A PHASE 1B/2 STUDY. (June 2017) - Matasar, M.; Herrera, A.F.; Kamdar, M.; Mehta, A.; Assouline, S.; Fleury, I.; Kim, T.M.; Kim, W.S.; Bosch, F.; Radford, J.; Flowers, C.R.; Bu, L.; et al.